Vasopharm Raises $6.5 mill For Phase III-Ready Traumatic Brain Injury Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
The tiny German biotech, vasopharm, aims to maximize the attractiveness of its NO-synthase inhibitor for potential partners, and to keep the flag flying for nitric oxide research.